Research programme: siRNA-based therapeutics - Calando Pharmaceuticals
Latest Information Update: 16 Mar 2012
At a glance
- Originator Calando Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 16 Mar 2012 No development reported - Preclinical for Sepsis in USA (IV)
- 08 Mar 2012 Added info about research collaboration with Axolabs - 9134432
- 09 Dec 2008 Preclinical trials in Sepsis in USA (IV)